China's CBMG Aims For Large-Scale CAR-T Capacity

06 Feb 2017

• By Emily Hayes

CBMG exec Tony Liu looks to differentiate CAR-T offerings partly based on ability to produce at a large scale in China, at a standard that matches the US.

Cellular Biomedicine Group Inc. aims to differentiate its chimeric antigen receptor T cell (CAR-T) therapy development in part by large-scale production in the company's home country, China, CEO Bizuo (Tony) Liu told Scrip’s Emily Hayes in an interview at the Biotech Showcase.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Scrip M&A Podcast: Will FDA Staff Cuts Impact Biopharma Dealmaking?

01 May 2025

• By Joseph Haas

Attorneys Andrew Goodman and Alan Minsk, as well as Naya CEO Daniel Teper, discussed the ramifications of US FDA staff cuts on M&A activity with Scrip senior writer Joseph Haas.